Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS23546 in Advanced Tumors
NCT06245122Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Mar 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CS23546 in solid tumor (advanced stage) and lymphoma (2 arms), sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
CS23546
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT06245122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06245122.